Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 17.67% is in line with its 5-year average of 16.76%, around the middle of its 5-year range (13.25%–21.81%).
3.26% above its 12-month average of 17.11%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 17.16%.
NET PROFIT MARGIN
17.67%
NET PROFIT MARGIN AVG TTM
17.11%
NET PROFIT MARGIN AVG 3Y
17.39%
NET PROFIT MARGIN AVG 5Y
16.76%
NET PROFIT MARGIN AVG 10Y
14.21%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.26%
CURRENT VS 3Y AVG
+1.62%
CURRENT VS 5Y AVG
+5.41%
CURRENT VS 10Y AVG
+24.33%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
9.21%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+91.96%
vs the sector median at left
Medpace Holdings, Inc.
Market Cap
$17.17B
Net Profit Margin
17.67%
TTM Avg
17.11%
3Y Avg
17.39%
5Y Avg
16.76%
Market Cap
$18.23B
Net Profit Margin
9.48%
TTM Avg
10.17%
3Y Avg
9.38%
5Y Avg
6.86%
Market Cap
$15.16B
Net Profit Margin
17.26%
TTM Avg
12.25%
3Y Avg
14.36%
5Y Avg
15.15%
Market Cap
$14.70B
Net Profit Margin
35.33%
TTM Avg
28.88%
3Y Avg
23.04%
5Y Avg
19.31%
Market Cap
$19.95B
Net Profit Margin
-2.79%
TTM Avg
-14.44%
3Y Avg
-3.94%
5Y Avg
-4.74%
Market Cap
$14.08B
Net Profit Margin
-17.77%
TTM Avg
-60.53%
3Y Avg
-62.93%
5Y Avg
-77.31%
Market Cap
$13.57B
Net Profit Margin
-5.96%
TTM Avg
-1.67%
3Y Avg
5.09%
5Y Avg
7.31%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $17.17B | 17.67% | 17.11% | 17.39% | 16.76% |
| Revvity, Inc. (RVTY)vs › | $16.37B | 8.16% | 9.60% | 8.02% | 12.66% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.23B | 9.48% | 10.17% | 9.38% | 6.86% |
| Solventum Corporation (SOLV)vs › | $15.16B | 17.26% | 12.25% | 14.36% | 15.15% |
| Exelixis, Inc. (EXEL)vs › | $14.70B | 35.33% | 28.88% | 23.04% | 19.31% |
| Viatris Inc. (VTRS)vs › | $19.95B | -2.79% | -14.44% | -3.94% | -4.74% |
| Tempus AI, Inc. (TEM)vs › | $14.08B | -17.77% | -60.53% | -62.93% | -77.31% |
| STERIS plc (STE)vs › | $20.28B | 13.33% | 12.25% | 8.55% | 8.79% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.57B | -5.96% | -1.67% | 5.09% | 7.31% |
| United Therapeutics Corporation (UTHR)vs › | $21.11B | 41.56% | 41.73% | 40.84% | 37.71% |
Operating Margin
21.0%
Net Profit Margin
17.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 17.16% |
| 2026-03-31 | 17.53% |
| 2025-12-31 | 19.07% |
| 2025-09-30 | 16.84% |
| 2025-06-30 | 14.96% |
| 2025-03-31 | 20.52% |
| 2024-12-31 | 21.81% |
| 2024-09-30 | 18.08% |
| 2024-06-30 | 16.73% |
| 2024-03-31 | 20.07% |
| 2023-12-31 | 15.71% |
| 2023-09-30 | 14.32% |
| 2023-06-30 | 13.25% |
| 2023-03-31 | 16.79% |
| 2022-12-31 | 17.42% |
| 2022-09-30 | 17.21% |
| 2022-06-30 | 14.05% |
| 2022-03-31 | 18.53% |
| 2021-12-31 | 16.22% |
| 2021-09-30 | 16.43% |
| 2021-06-30 | 14.35% |
| 2021-03-31 | 16.66% |
| 2020-12-31 | 19.59% |
| 2020-09-30 | 18.00% |
| 2020-06-30 | 11.76% |
| 2020-03-31 | 12.54% |
| 2019-12-31 | 12.97% |
| 2019-09-30 | 11.09% |
| 2019-06-30 | 12.82% |
| 2019-03-31 | 9.56% |
| 2018-12-31 | 11.85% |
| 2018-09-30 | 10.77% |
| 2018-06-30 | 9.74% |
| 2018-03-31 | 8.92% |
| 2017-12-31 | 10.02% |
| 2017-09-30 | 8.89% |
| 2017-06-30 | 8.99% |
| 2017-03-31 | 7.92% |
| 2016-12-31 | -0.02% |
| 2016-09-30 | 4.67% |
| 2016-06-30 | 4.68% |
| 2016-03-31 | 3.46% |
| 2015-12-31 | -8.93% |
| 2015-09-30 | -0.14% |
| 2015-06-30 | 0.11% |
| 2015-03-31 | -0.07% |
| 2014-03-31 | -1.59% |
